Merck Animal Health Pioneers H3N2 Canine Influenza Vaccine

Dateline City: MADISON, N.J. Innovative Addition Further Strengthens CIV Product Line Madison, N.J. - In response to the H3N2 canine influenza (CIV) outbreaks that impacted dogs in 241 states, Merck Animal Health (known as MSD Animal Health outside the United States and Canada) today announced the U.S. Department of Agriculture (USDA) has issued a conditional product license for a vaccine to protect against this newly identified strain of CIV. Canine Influenza Vaccine H3N2 will be available to U.S. veterinarians beginning Monday, November 23. Language: English read more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Corporate News Animal Health Latest News Source Type: news